We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales for the full year.
Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.
Annexon (ANNX) is expected to provide updates from the phase III study evaluating its lead candidate, ANX005, for the treatment of GBS in the first-quarter earnings release.
Eli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.
Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
Pre-market futures are up across the board: +106 points on the Dow, +45 points on the S&P 500 and +195 on the Nasdaq immediately following this important data's release.
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
pharmaceuticals: Archive
Company News for May 2, 2024
by Zacks Equity Research
Companies In The News Are: CVS, PFE, PPL, ADP.
PPLPositive Net Change ADPPositive Net Change PFEPositive Net Change CVSNegative Net Change
business-services pharmaceuticals utilities
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
by Zacks Equity Research
Pfizer (PFE) beats first-quarter estimates for earnings and sales. It raises 2024 earnings guidance while retaining revenue expectations.
PFEPositive Net Change LGNDPositive Net Change ANIPPositive Net Change BNTXPositive Net Change
pharmaceuticals
GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance
by Zacks Equity Research
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales for the full year.
GSKPositive Net Change JNJPositive Net Change ANIPPositive Net Change VIRPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
by Sweta Killa
Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.
LLYNegative Net Change XLVPositive Net Change IYHPositive Net Change IHEPositive Net Change PPHPositive Net Change MEDXPositive Net Change
earnings etfs pharmaceuticals
Annexon (ANNX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Annexon (ANNX) is expected to provide updates from the phase III study evaluating its lead candidate, ANX005, for the treatment of GBS in the first-quarter earnings release.
ALNYPositive Net Change ATRANegative Net Change ARGXPositive Net Change ANNXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
by Zacks Equity Research
Exelixis (EXEL) misses on earnings and sales in the first quarter. Its shares are trading down in response to the results.
EXELNegative Net Change AMRNNegative Net Change ANIPPositive Net Change VYGRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Company News for May 1, 2024
by Zacks Equity Research
Companies In The News Are: PYPL, LLY, MMM, GLW.
LLYNegative Net Change MMMPositive Net Change GLWPositive Net Change PYPLNegative Net Change
communications internet multi-sector-conglomerates pharmaceuticals
These 3 Companies Recently Lifted Guidance
by Derek Lewis
Guidance lifts are among the most positive announcements shareholders can hear, injecting confidence in the long-term picture.
KOPositive Net Change LLYNegative Net Change ETNNegative Net Change
consumer-staples pharmaceuticals utilities
Eli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised
by Zacks Equity Research
Eli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.
NVOPositive Net Change LLYNegative Net Change LGNDPositive Net Change ANIPPositive Net Change
pharmaceuticals
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
by Zacks Equity Research
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
REGNPositive Net Change PFEPositive Net Change NVOPositive Net Change AMGNPositive Net Change MRNAPositive Net Change
biotechs earnings gene-therapy immuno-therapy medical messenger-rna pharmaceuticals vaccines
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge.
AMZNPositive Net Change KOPositive Net Change LLYNegative Net Change MMMPositive Net Change SBUXNegative Net Change MCDPositive Net Change SMCINegative Net Change
consumer-staples multi-sector-conglomerates pharmaceuticals restaurants
Pre-Markets Sell on Last Trading Day of April
by Mark Vickery
Today we close out a month that's likely to be the first negative one since October of last year.
AMZNPositive Net Change KOPositive Net Change LLYNegative Net Change MMMPositive Net Change SBUXNegative Net Change MCDPositive Net Change SMCINegative Net Change
consumer-discretionary earnings industrial-products pharmaceuticals
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
ALNYPositive Net Change VRTXPositive Net Change CRSPPositive Net Change ALPNPositive Net Change
biotechnology biotechs crispr earnings gene-editing gene-therapy medical pharmaceuticals
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
MRKNegative Net Change MRNAPositive Net Change SRPTPositive Net Change ARGXPositive Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
Collegium (COLL) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Collegium's (COLL) top line is likely to have been fueled by growth in the sales of pain drugs, Belbuca and Xtampza ER, in the first quarter of 2024.
UTHRPositive Net Change EXELNegative Net Change SRPTPositive Net Change COLLPositive Net Change
biotechs earnings pharmaceuticals
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.
ALNYPositive Net Change SRPTPositive Net Change ARGXPositive Net Change OCGNPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
by Zacks Equity Research
AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.
RHHBYNegative Net Change JNJPositive Net Change ABBVNegative Net Change GMABPositive Net Change
biotechs earnings medical pharmaceuticals
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
by Kinjel Shah
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
SNYPositive Net Change AZNPositive Net Change NVSPositive Net Change JNJPositive Net Change MRKNegative Net Change
pharmaceuticals
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
by Zacks Equity Research
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
BIIBPositive Net Change LGNDPositive Net Change ANIPPositive Net Change SAGENegative Net Change
biotechs medical pharmaceuticals
PCE/Core PCE Numbers Came In Line With Expectations
by Zacks Equity Research
PCE/Core PCE Numbers Came In Line With Expectations
XOMNegative Net Change ABBVNegative Net Change
oil-energy pharmaceuticals
PCE In-Line to Warmer, Pre-Market Calms; ABBV Beats, XOM Misses
by Mark Vickery
Pre-market futures are up across the board: +106 points on the Dow, +45 points on the S&P 500 and +195 on the Nasdaq immediately following this important data's release.
XOMNegative Net Change ABBVNegative Net Change
consumer-discretionary consumer-staples energy inflation pharmaceuticals
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
GILDPositive Net Change ANIPPositive Net Change ADMAPositive Net Change XLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
AZNPositive Net Change MRKNegative Net Change SRPTPositive Net Change FUSNNegative Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
5 Stocks in Focus on Their Recent Dividend Hike
by Nalak Das
Five stocks to focus with recent dividend hike are: JNJ, TRV, SON, KBH, SPFI.
JNJPositive Net Change TRVPositive Net Change SONPositive Net Change KBHPositive Net Change SPFIPositive Net Change
business-services construction finance industrial-products pharmaceuticals
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
by Zacks Equity Research
Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
BIIBPositive Net Change BMYPositive Net Change VRTXPositive Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals